Edwards Lifesciences Corp/ US28176E1082 /
04/09/2024 21:59:57 | Chg. +0.18 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
68.92USD | +0.26% | 155,524 Turnover: 10.75 mill. |
-Bid Size: - | -Ask Size: - | 41.52 bill.USD | - | 29.84 |
Assets
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 679.7000 | 867.5000 | 1,060.3000 | 1,395.2000 | 1,546.6000 | ||||||
Intangible Assets | 468 | 343.2000 | 336.5000 | 331.4000 | 323.6000 | ||||||
Long-Term Investments | 567 | 506.3000 | 585.5000 | 801.6000 | 1,834.2000 | ||||||
Fixed Assets | 3,163.7000 | 3,036.8000 | 3,504.1000 | 4,146.1000 | 5,321.9000 | ||||||
Inventories | 554.9000 | 607 | 640.9000 | 802.3000 | 726.7000 | ||||||
Accounts Receivable | 421.6000 | 456.9000 | 543.6000 | 514.6000 | 582.2000 | ||||||
Cash and Cash Equivalents | 818.3000 | 714.1000 | 1,179.1000 | 1,183.2000 | 862.8000 | ||||||
Current Assets | 2,532.1000 | 2,286.9000 | 2,984 | 3,091 | 3,180.7000 | ||||||
Total Assets | 5,695.8000 | 5,323.7000 | 6,488.1000 | 7,237.1000 | 8,502.6000 |
Liabilities
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 116.6000 | 134 | 180.4000 | 196.5000 | 204.5000 | ||||||
Long-term debt | 438.4000 | 593.8000 | 594.4000 | 595 | 595.7000 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | 636.6000 | 876.6000 | 696.5000 | 670.2000 | 802.3000 | ||||||
Liabilities | 2,739.6000 | 2,183.3000 | 2,339.8000 | 2,662.8000 | 2,666.7000 | ||||||
Share Capital | 636 | 645.6000 | 654.3000 | 636.4000 | 642 | ||||||
Total Equity | 2,956.2000 | 3,140.4000 | 4,148.3000 | 4,574.3000 | 5,835.9000 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 5,695.8000 | 5,323.7000 | 6,488.1000 | 7,237.1000 | 8,502.6000 |
Income Statement
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 3,435.3000 | 3,722.8000 | 4,348 | 4,386.3000 | 5,232.5000 | ||||||
Depreciation (total) | - | - | - | - | - | ||||||
Operating Result | 1,089.4000 | 748.2000 | 1,146.8000 | 897.6000 | 1,690.3000 | ||||||
Interest Income | 2.9000 | -2.1000 | -11.5000 | -7.6000 | 1 | ||||||
Income Before Taxes | 1,034.9000 | 761.4000 | 1,166.5000 | 916.7000 | 1,702 | ||||||
Income Taxes | 451.3000 | 39.2000 | 119.6000 | 93.3000 | 198.9000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 583.6000 | 722.2000 | 1,046.9000 | 823.4000 | 1,503.1000 |
Per Share
Cash Flow
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 1,000.7000 | 926.8000 | 1,179.4000 | 1,054.3000 | 1,732.1000 | ||||||
Cash Flow from Investing Activities | -647.2000 | 76.7000 | -595.8000 | -531.1000 | -1,722.5000 | ||||||
Cash Flow from Financing | -473.2000 | -1,101.2000 | -115.6000 | -486.9000 | -356.3000 | ||||||
Decrease / Increase in Cash | -111.8000 | -104.2000 | 465 | 15.8000 | -332.8000 | ||||||
Employees | 12,200 | 12,800 | 13,900 | 14,900 | 15,700 |